Patents Assigned to Chong Kun Dang Pharmaceutical Corp.
-
Patent number: 9173853Abstract: Disclosed is a pharmaceutical composition for gene delivery, comprising: (i) a gene; (ii) a water-soluble chitosan; (iii) a thiamine pyrophosphate or a pharmaceutically acceptable salt thereof; (iv) a protamine or a pharmaceutically acceptable salt thereof; and (v) a neutral or anionic phospholipid. The composition can introduce a gene into cells safely and effectively. Composed of non-toxic and injectable components, the composition is safe for the body and can be advantageously commercialized. Notably, it can deliver a gene at high efficiency in vivo as well as in vitro, and is stable in the blood.Type: GrantFiled: November 9, 2012Date of Patent: November 3, 2015Assignee: Chong Kun Dang Pharmaceutical Corp.Inventors: Young Nam Lee, Ho Young Hwang, Sang Myoung Noh, Hee-Jeong Cho, Ah-Reum Chae, Ji Hee Lee, Min Hyo Ki, Jong Lae Lim
-
Publication number: 20150252030Abstract: The present invention relates to novel N-acylhydrazone derivatives, and more particularly to novel N-acylhydrazone derivatives having selective T cell inhibitory activity and/or anti-lymphoid malignancy activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, the use thereof for preparing pharmaceutical compositions, pharmaceutical compositions containing the same, treatment methods using the compositions, and methods for preparing the novel N-acylhydrazone derivatives.Type: ApplicationFiled: August 29, 2013Publication date: September 10, 2015Applicants: CHONG KUN DANG PHARMACEUTICAL CORP., INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: HoJin Choi, JaeWon Lee, ChangGon Lee, NiNa Ha, Su Kil Seo, SunMi Lee, Song-Min Lee
-
Publication number: 20150166480Abstract: The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.Type: ApplicationFiled: June 11, 2013Publication date: June 18, 2015Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: ChangSik Lee, TaegSu Jang, DaeKyu Choi, MooSung Ko, DoHoon Kim, SoYoung Kim, JaeKi Min, WooSik Kim, YoungTae Lim
-
Publication number: 20150119376Abstract: The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition. It means that the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.Type: ApplicationFiled: April 12, 2012Publication date: April 30, 2015Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: SeoHee LEE, JungTaek OH, JaeKwang LEE, JaeWon LEE, Suyeal BAE, Nina HA, Sera LEE
-
Publication number: 20150110876Abstract: Disclosed is a pharmaceutical composition for gene delivery, comprising: (i) a gene; (ii) a water-soluble chitosan; (iii) a thiamine pyrophosphate or a pharmaceutically acceptable salt thereof; (iv) a protamine or a pharmaceutically acceptable salt thereof; and (v) a neutral or anionic phospholipid. The composition can introduce a gene into cells safely and effectively. Composed of non-toxic and injectable components, the composition is safe for the body and can be advantageously commercialized. Notably, it can deliver a gene at high efficiency in vivo as well as in vitro, and is stable in the blood.Type: ApplicationFiled: November 9, 2012Publication date: April 23, 2015Applicant: Chong Kun Dang Pharmaceutical Corp.Inventors: Young Nam Lee, Ho Young Hwang, Sang Myoung Noh, Hee-Jeong Cho, Ah-Reum Chae, Ji Hee Lee, Min Hyo Ki, Jong Lae Lim
-
Publication number: 20140315889Abstract: The present invention relates to a novel hydroxamate derivatives, more specifically, to novel hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC), isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof, use for preparing pharmaceutical compositions, pharmaceutical compositions comprising the same, treatment method using said composition, and a preparing method of novel hydroxamate derivatives. The novel selective hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC) compositions can be used for treatment of inflammatory disease, rheumatoid arthritis, or degenerative disease.Type: ApplicationFiled: October 26, 2012Publication date: October 23, 2014Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Yuntae Kim, Changsik Lee, Hyun-mo Yang, Hojin Choi, Jaeki Min, Soyoung Kim, Dal-Hyun Kim, Nina Ha, Jung-Min Kim, Hyojin Lim, Eunhee Ko
-
Publication number: 20140243510Abstract: The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an N-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic acid residues, can be effectively purified via three-step chromatographic processes in short time at lower cost.Type: ApplicationFiled: September 28, 2012Publication date: August 28, 2014Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Yeo-Wook Koh, Sang-Yong Lee, Cook-Hee Kim, Seung-Hui Lee, Ha-Na Kim, Su-Yon Kim, Jin-Hyun Seong, Yong-Hyun Cho
-
Publication number: 20140206616Abstract: Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.Type: ApplicationFiled: August 28, 2012Publication date: July 24, 2014Applicant: Chong Kun Dang Pharmaceutical Corp.Inventors: Jin Young Ko, Ji Yeon Kim, So Hyun Park, Sung Won An, Min Hyo Ki
-
Publication number: 20140093914Abstract: The present invention relates to an expression vector for animal cells, comprising: (a) CSP-B (Cytotoxic Serine Protease-B) 5?-SAR (Scaffold or Matrix Attachment Region); (b) a promoter operable in animal cells; and (c) a polyadenylation sequence, and to a method for producing recombinant proteins using same. The vector of the present invention includes CSP-B 5?-SAR, and thus has the effect of overcoming the inhibition of gene expression according to the position of a foreign gene introduced into an animal cell, and significantly improving the expression rate of a target protein. The vector of the present invention effectively expresses recombinant proteins for drugs or antibodies in animal cells. The vector of the present invention and the method for producing recombinant proteins using same may be very usefully applied to the industrial mass production of drugs.Type: ApplicationFiled: May 21, 2012Publication date: April 3, 2014Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Yeo-Wook Koh, Sang-Yong Lee, Su-Yon Kim, Seung-kee Moon
-
Publication number: 20140031335Abstract: The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition. It means that the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.Type: ApplicationFiled: April 12, 2012Publication date: January 30, 2014Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: SeoHee Lee, Jung Taek Oh, JaeKwang Lee, JaeWon Lee, Suyeal Bae, Nina Ha, Sera Lee
-
Patent number: 8524914Abstract: The present invention relates to novel intermediate compounds used in preparing Rosuvastatin or the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a method for preparing Rosuvastatin or the pharmaceutically acceptable salts thereof from the intermediates. The preparation method of the present invention has the effect of providing Rosuvastatin hemi-calcium salts with an excellent yield rate.Type: GrantFiled: April 8, 2010Date of Patent: September 3, 2013Assignee: Chong Kun Dang Pharmaceutical Corp.Inventors: Hongwoo Lee, Daejong Park, Choongleol Yoo, Donghyuk Nam, Hohyung Ryu, Dongjin Kim
-
Patent number: 8466161Abstract: The present invention relates to hydroxamate compounds of the following formula I, an isomer, pharmaceutically acceptable salt or hydrate thereof. The present invention also relates to a method for preparing the hydroxamate compounds, comprising allowing a compound of the following formula II to react with bromoaniline in the presence of an inorganic salt so as to prepare a compound of the following formula III.Type: GrantFiled: March 18, 2010Date of Patent: June 18, 2013Assignee: Chong Kun Dang Pharmaceutical Corp.Inventors: Sung Sook Lee, Kyung Joo Lee, Chang Sik Lee, Hyun Mo Yang, Do Hoon Kim, Dae Kyu Choi, Ho Jin Choi, Dal Hyun Kim, In Chang Hwang, Mi Jeong Kim, Byeong Hoon Han
-
Patent number: 8362267Abstract: Disclosed are a novel thiazole-containing benzophenone derivative represented by formula 1, and an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof, a pharmaceutical composition comprising the derivative, a use of the derivative as therapeutic agent and a method for preparing the derivative. The benzophenone thiazole derivatives inhibit formation of microtubules and eliminate actively proliferating cells of malignant tumors to control general cell proliferation. In formula 1, R, R1 and R2 are defined as above.Type: GrantFiled: March 5, 2009Date of Patent: January 29, 2013Assignee: Chong Kun Dang Pharmaceutical Corp.Inventors: Nam-Song Choi, Young-Hoon Kim, Jae-Kwang Lee, Hee-Ryong Kang, Ho-Jin Choi, Seung-Kee Moon, Soo-Jin Kim, Gyu-Tae Park, Byeong-Hoon Han, Dal-Hyun Kim, Jae-Hoon Choi, Sung-Sook Lee, Soon-Kil Ahn, Kyung-Joo Lee, Su-Yeal Bae
-
Patent number: 8178697Abstract: The present invention relates to a novel method for preparing atorvastatin. According to the present invention, provided are a novel intermediate of the preparation of atorvastatin and a method of preparing large amounts of atorvastatin in a safe manner using the intermediate.Type: GrantFiled: April 25, 2008Date of Patent: May 15, 2012Assignee: Chong Kun Dang Pharmaceutical Corp.Inventors: Soon Kil Ahn, Hong-Woo Lee, Choong Leol Yoo, Young-Min Kim, Chang Geun Song, Sung Kwun Kang, Jun A. You, Bong Kwan Soh, Dong Hyuk Nam
-
Publication number: 20120028963Abstract: The present invention relates to hydroxamate derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, the use thereof for preparing pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the compositions, and a method for preparing the hydroxamate derivatives.Type: ApplicationFiled: March 18, 2010Publication date: February 2, 2012Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Sung Sook Lee, Kyung Joo Lee, Chang Sik Lee, Hyun Mo Yang, Do Hoon Kim, Dae Kyu Choi, Ho Jin Choi, Dal Hyun Kim, In Chang Hwang, Mi Jeong Kim, Byeong Hoon Han
-
Patent number: 8053439Abstract: Disclosed herein are novel benzophenone derivatives represented by formula I, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, a pharmacological composition containing the same, and a use of the composition as therapeutic drugs. The benzophenone derivatives have an inhibition activity of microtubule formation and can be used to treat a normal proliferative state of a malignant tumor by killing the actively proliferating cells.Type: GrantFiled: September 21, 2007Date of Patent: November 8, 2011Assignee: Chong Kun Dang Pharmaceutical Corp.Inventors: Nam-Song Choi, Young-Mi Kim, Young-Hoon Kim, Jae-Kwang Lee, In-Taek Lim, Ho-Jin Choi, Hyun-Mo Yang, Seung-Kee Moon, Soo-Jin Kim, Hyun-Jung Yu, Jae-Su Shin, Young-Min Kwon, Sung-Sook Lee, Soon-Kil Ahn, Sun-Ju Kong
-
Publication number: 20110021582Abstract: Disclosed are a novel thiazole-containing benzophenone derivative represented by formula 1, and an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof, a pharmaceutical composition comprising the derivative, a use of the derivative as therapeutic agent and a method for preparing the derivative. The benzophenone thiazole derivatives inhibit formation of microtubules and eliminate actively proliferating cells of malignant tumors to control general cell proliferation. In formula 1, R, R1 and R2 are defined as above.Type: ApplicationFiled: March 5, 2009Publication date: January 27, 2011Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Nam-Song Choi, Young-Hoon Kim, Jae-Kwang Lee, Hee-Ryong Kang, Ho-Jin Choi, Seung-Kee Moon, Soo-Jin Kim, Gyu-Tae Park, Byeong-Hoon Han, Dal-Hyun Kim, Jae-Hoon Choi, Sung-Sook Lee, Soon-Kil Ahn, Kyung-Joo Lee, Su-Yeal Bae
-
Publication number: 20110015407Abstract: The present invention relates to a novel method for preparing atorvastatin. According to the present invention, provided are a novel intermediate of the preparation of atorvastatin and a method of preparing large amounts of atorvastatin in a safe manner using the intermediate.Type: ApplicationFiled: April 25, 2008Publication date: January 20, 2011Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Soon Kil Ahn, Hong-Woo Lee, Choong Leol Yoo, Young-Min Kim, Chang Geun Song, Sung Kwun Kang, Jun A. You, Bong Kwan Soh, Dong Hyuk Nam
-
Patent number: 7718695Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.Type: GrantFiled: July 25, 2007Date of Patent: May 18, 2010Assignee: Chong Kun Dang Pharmaceutical Corp.Inventors: Jae Hyun Kim, Su Kyung Lee, Won Kyu Choi, Jong Lae Lim, Soon Kil Ahn, Hee Jong Shin, Chung Il Hong
-
Publication number: 20100056623Abstract: The present invention relates to a fumagillol derivative, pharmaceutically acceptable salts thereof and a method for preparing the same. The compounds of the present invention can be prepared through acylation, hydrolysis and alkylation. The compound of the present invention can be prepared in the form of a pharmaceutically acceptable salt or inclusion compound. The present invention provides fumagillol derivatives having the following characteristics: increased inhibiting effect on angiogenesis, low toxicity, excellent solubility and chemical stability as compared to conventional angiogenesis inhibitors. The compounds of the present invention can be used as an anti-cancer medicine, inhibitor of cancer metastasis, or the therapeutic agent for treating rheumatic arthritis, psoriasis, diabetic retinitis or obesity.Type: ApplicationFiled: January 26, 2005Publication date: March 4, 2010Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Sang Joon Lee, Soon Kil Ahn, Hong Woo Lee, Joong Bok Ahn, Jae Soo Shin, Young Min Kwon